

# Characteristics of binding sites of intergenic, intronic and exonic miRNAs with mRNAs of oncogenes coding intronic miRNAs

Olga Berillo, Assel Issabekova, Mireille Regnier, Anatoly Ivashchenko

► **To cite this version:**

Olga Berillo, Assel Issabekova, Mireille Regnier, Anatoly Ivashchenko. Characteristics of binding sites of intergenic, intronic and exonic miRNAs with mRNAs of oncogenes coding intronic miRNAs. African Journal of Biotechnology, Academic Journals, 2013, 12 (10), pp.1016-1024. <http://www.academicjournals.org/ajb/PDF/pdf2013/6Mar/Berillo%20et%20al.pdf> . 10.5897/AJB12.2054 . hal-00825020

**HAL Id: hal-00825020**

**<https://hal.inria.fr/hal-00825020>**

Submitted on 22 May 2013

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

*Full Length Research Paper*

# Characteristics of binding sites of intergenic, intronic and exonic miRNAs with mRNAs of oncogenes coding intronic miRNAs

Olga A. Berillo<sup>1\*</sup>, Assel S. Issabekova<sup>1</sup>, Mireille Régnier<sup>2</sup> and Anatoliy T. Ivashchenko<sup>1</sup>

<sup>1</sup>Department of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty 050038, Kazakhstan.  
<sup>2</sup>INRIA/LIX team AMIB 1 rue Honoré d'Estienne d'Orves 91120 Palaiseau, France.

Accepted 2 October, 2012

The interaction of 784 intergenic (ig-miRNA), 686 intronic (in-miRNA) and 49 exonic miRNAs (ex-miRNA) with mRNAs of 51 oncogenes coding in-miRNAs was investigated. Out of the studied genes, 44 were targets for 94 ig-miRNAs, 29 were targets for 44 in-miRNAs and 7 were targets for 7 ex-miRNAs. The density of miRNA binding sites was higher in 5'-untranslated regions than it was in coding sequences and 3'-untranslated regions. Three types of miRNA interaction with mRNA were revealed: 5'-dominant canonical, 3'-compensatory and complementary types. In-miRNAs do not interact with mRNAs of host genes (where in-miRNA is encoded). Linkage between some mRNAs of genes encodes in-miRNAs via other in-miRNAs was revealed. These data promote the understanding of interaction mechanism of miRNA with mRNA genes participating in gastrointestinal and breast cancers.

**Key words:** Intergenic miRNA, intronic miRNA, exonic miRNA, mRNA, 5'-untranslated region, coding sequences, 3'-untranslated region, human, oncogene.

## INTRODUCTION

MicroRNAs (miRNA) are non-protein coding RNA sequences that have length of about 22 nucleotides (nt). miRNA are evolutionary conservative in many organisms and accomplishes important regulatory function (Ibanez-Ventoso et al., 2008). The binding miRNA with mRNA leads to specific splitting, deadenylation or translation repression (Pillai et al., 2007). miRNA genes can be encoded in the intergenic or intragenic regions. Intragenic miRNAs are situated within intron or exon of their host genes (Kim and Kim, 2007). Some of the miRNAs are found on border of exon and intron (Rodriguez et al., 2004). The number of miRNA is considerably enlarged due to new methods of search and comparison of targets. miRNAs regulate translation of about 60% of all human protein-coding genes (Friedman et al., 2009). mRNA can have some binding sites with one or with several miRNAs. Hence, the influence of miRNA on inhibition of

mRNA translation becomes greater (Baek et al., 2008; Selbach et al., 2008; Grimson et al., 2007). Deregulation in miRNA expression is one main cause of cancer (Hamano et al., 2011), cardiovascular (Small et al., 2010) and other diseases (Jiang et al., 2010). Aberrant miRNA expression has been well characterized in different oncology diseases and their progression (Cortez et al., 2012). Expression of some miRNAs is changed in development esophageal cancer (Fang et al., 2012), gastric cancer (Lu et al., 2011), colorectal cancer (Hamfjord et al., 2012), breast cancer (Hafez et al., 2012; Hanna et al., 2012) and other cancer types.

Many programs for miRNA binding sites prediction have been developed (Sethupathy et al., 2006). A search for miRNA sites are based on revealing of complementary seed (part of 5'-end miRNA site). The programs have algorithms for identification of RNA seed with length from 6 to 8 nt (Friedman et al., 2009; Lewis et al., 2003). Site searching for only short seed leads to the prediction of considerable quantity of false sites. Some programs take the advantage of seed conservation to assess site specificity. However, there are many nonconservative

\*Corresponding author. E-mail: [devolia18@mail.ru](mailto:devolia18@mail.ru). Tel/Fax: +7 (727) 377 32 02.

seed-site of miRNAs already known (Baek et al., 2008). Some programs predict not perfectly complementary seed in the presence of 3'-compensatory site (Farh et al., 2005).

Most programs allow search for sites only in 3'-untranslated regions (3'UTR) (Maragkakis et al., 2011). It has been shown that miRNA sites may also occur in open reading frame (ORF) (Baek et al., 2008). Many researchers consider that miRNAs interact with mRNAs only in 3'UTR (Delay et al., 2011; Iorio et al., 2009; Isik et al., 2010; Kruger and Rehmsmeier, 2006; Satoh and Tabunoki, 2011), however, publications which describe miRNAs binding to mRNAs in 5'-untranslated regions (5'UTR) and coding sequences (CDS) are known (Duursma et al., 2008; Elcheva et al., 2009; Kulkarni et al., 2011; Moretti et al., 2010; Tsai et al., 2009).

MiRNA binding sites, predicted by computer method, which is founded by obligatory complementarity of 5'-seed region, are checked experimentally. However, some other miRNA binding sites, based on 3'-compensatory type, are not predicted by such method, but they are identified in experiments (Qin et al., 2010; Shirdel et al., 2011).

Program RNAhybrid (<http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/>) relies on thermodynamics and allows the search for 5'-dominant initial, 5'-seed-dominant and 3'-compensatory types of target sites (Garcna et al., 2011). An accurate identification of miRNA:mRNA pairs should promote considerable development of diagnostic methods of various cancer diseases.

The present research aimed to reveal miRNA binding sites with various parts of mRNA (5'UTR, CDS and 3'UTR) and defined nucleotide interaction features of miRNA:mRNA complexes. This study was realized for miRNAs involved in cancer and should be extended to other genes.

## MATERIALS AND METHODS

Nucleotide sequences of miRNAs and their precursors were found from miRBase (<http://www.mirbase.org>). Nucleotide sequences mRNAs of all genes (Homo sapiens, Genome build 37.2.) were obtained from GenBank (<http://www.ncbi.nlm.nih.gov>). Then, miRNAfinder 2.2 (<https://sites.google.com/site/malaheenee/home>) was used to find miRNA origins (intergenic, exonic or intronic). A literature review of genes coding intronic miRNAs led to 51 oncogenes (Supplementary Table 1) that encode proteins participating in gastrointestinal and breast cancer. This information was collected according to articles from US National Library of Medicine, National Institutes of Health PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>).

RNAhybrid 2.1 was run for all pairs (miRNA:mRNA complexes) and provided positions of potential binding sites miRNAs in mRNAs, free energy of miRNA binding sites ( $\Delta G$ ) and scheme of their interaction.

The script E-RNAhybrid (<https://sites.google.com/site/malaheenee/home>) computes the ratio  $\Delta G/\Delta G_m$ , p-value, equalizing coefficient and type of corresponding regions (5'UTR, CDS or 3'UTR), where miRNA site disposes. To achieve this, a quantitative criterion was defined. A ratio  $\Delta G/\Delta G_m$

was measured as percentage, where  $\Delta G_m$  equals binding energy for miRNA with perfectly complementary nucleotide sequence computed. Number of binding sites in 5'UTR, CDS and 3'UTR was calculated as the number of sites (s) divided to nucleotide length (l) of this region and multiplied by  $10^3$  (s/l), that is, calculation per 1000 nucleotides. Significance degree (p-value) was estimated, that relies on  $\Delta G$  and its standard deviation. The binding sites had ratio  $\Delta G/\Delta G_m$  that equals or more than 80%.

## RESULTS

784 intergenic, 686 intronic and 49 exonic miRNAs were found by program miRNAfinder 2.2. 471 genes encode 686 intronic pre-miRNAs. In these genes are situated one or more in-miRNAs. Among them, only 51 genes encode proteins participating in the development of gastrointestinal and breast cancer according to literature reviewed of all these genes (Supplementary Table 1).

Interaction of all studied miRNAs with mRNAs of 51 oncogenes was investigated by script E-RNAhybrid. The obtained results show a linkage between several mRNA of genes encoding in-miRNAs via other in-miRNAs (these miRNAs localize in genes that are not targets). Similar results can be found on three types of miRNA. It was established that all mRNA regions (5'UTR, CDS and 3'UTR) have miRNA binding sites. The density of sites and their distribution on these mRNA regions was revealed. Complementary type of miRNA binding sites was found.

### Interaction of intergenic miRNA with mRNA oncogenes coding in-miRNA

Binding sites of 784 ig-miRNAs with 51 mRNAs were studied. Shares of binding sites for ig-miRNAs were 16.7, 57.3 and 26.0% in 5'UTR, CDS, 3'UTR of mRNAs, respectively. However, the density of binding sites in 5'UTR, CDS and 3'UTR mRNA was 2.32, 0.88 and 0.80 s/l, respectively, for these genes. Ig-miRNA binding sites with the best characteristics are represented in Tables 1 to 3. 5'UTR of some mRNAs can have several miRNA binding sites despite their short length (Table 1). For example, *NR2F2* gene had four binding sites; *EPCAM*, *HNF4A* and *SLIT3* genes have three sites and *EGFL7*, *HDAC4*, *LRP1* genes have two sites in 5'UTR. Several miRNAs have some targets of studied genes. MiR-4472 had binding sites in CDS of 7 genes (*AATK*, *HDAC4*, *LRP1*, *MAP2K4*, *NOTCH1*, *PTPRJ* and *SLIT3*), where *LRP1* gene has three sites and *NOTCH1* gene has two sites (Table 2). MiR-4456, miR-4455 and miR-4711-3p had binding sites in CDS six, five and four mRNAs accordingly. These miRNAs are important as they have binding sites with many mRNAs of studied genes. Characteristics of site location in 3'UTR were the same as in 5'UTR and CDS (Table 3). *BRE*, *IGF1R* and *MRE11A* genes were targets for miR-4456; *BBC3* and *NOTCH1* genes were targets for miR-1587. mRNA *BBC3*

**Table 1.** Positions of ig-miRNA binding sites in 5'UTR mRNA.

Target gene	miRNA	Position (nt)	Target gene	miRNA	Position (nt)	Target gene	miRNA	Position (nt)
<i>AATK</i>	miR-4417	45	<i>HDAC4</i>	miR-1268	80	<i>NR2F2</i>	miR-4253	537
<i>ATF2</i>	miR-4319	63	<i>HNF4A</i>	miR-302f	71	<i>NR2F2</i>	miR-4787-5p	1152
<i>BRE</i>	miR-4455	39	<i>HNF4A</i>	miR-1279	1	<i>PRKG1</i>	miR-1268	142
<i>DCC</i>	miR-568	524	<i>HNF4A</i>	miR-4307	76	<i>PTK2</i>	miR-3676	22
<i>DTL</i>	miR-4309	44	<i>HUWE1</i>	miR-4266	134	<i>PTPRJ</i>	miR-3195	288
<i>EGFL7</i>	miR-4289	4	<i>LRP1</i>	miR-4307	188	<i>SDCCAG8</i>	miR-4309	20
<i>EGFL7</i>	miR-1204	301	<i>LRP1</i>	miR-4472	99	<i>SLIT3</i>	miR-4507	61
<i>EPCAM</i>	miR-4456	112	<i>MCM7</i>	miR-4289	453	<i>SLIT3</i>	miR-4466	253
<i>EPCAM</i>	miR-4492	137	<i>MTUS1</i>	miR-3195	141	<i>SLIT3</i>	miR-4481	314
<i>EPCAM</i>	miR-4508	140	<i>NR2F2</i>	miR-4443	556	<i>SPATA13</i>	miR-4279	12
<i>HDAC4</i>	miR-3195	266	<i>NR2F2</i>	miR-1538	289	-	-	-

**Table 2.** Positions of ig-miRNA binding sites in CDS mRNA.

Target gene	miRNA	Position (nt)	Target gene	miRNA	Position (nt)	Target gene	miRNA	Position (nt)
<i>AATK</i>	miR-1538	1339	<i>EPHB2</i>	miR-4316	1293	<i>LRP1</i>	miR-4266	5093
<i>AATK</i>	miR-3195	1352	<i>EPHB2</i>	miR-4466	1334	<i>LRP1</i>	miR-4283	12932
<i>AATK</i>	miR-4265	3143	<i>ERBB4</i>	miR-4443	1940	<i>LRP1</i>	miR-4455	12015
<i>AATK</i>	miR-4472	1684	<i>EVL</i>	miR-3180	816	<i>LRP1</i>	miR-4456	2930
<i>AATK</i>	miR-4492	3345	<i>EVL</i>	miR-4711-3p	802	<i>LRP1</i>	miR-4472	13015
<i>AATK</i>	miR-4711-3p	2715	<i>FOXP1</i>	miR-320d	2225	<i>LRP1</i>	miR-4472	11274
<i>AKT2</i>	miR-4492	1370	<i>FOXP1</i>	miR-1279	2111	<i>LRP1</i>	miR-4472	2781
<i>ANTXR1</i>	miR-3141	2010	<i>FOXP1</i>	miR-4264	2506	<i>MAP2K4</i>	miR-4472	120
<i>ANTXR1</i>	miR-4711-3p	1772	<i>FOXP1</i>	miR-4266	1126	<i>MAP7D2</i>	miR-4417	1395
<i>BBC3</i>	miR-3665	410	<i>FOXP1</i>	miR-4327	2392	<i>MCM7</i>	miR-4483	1975
<i>BBC3</i>	miR-4278	884	<i>FOXP1</i>	miR-4736	1146	<i>MRE11A</i>	miR-302f	852
<i>BBC3</i>	miR-4466	319	<i>GIPR</i>	miR-659	1441	<i>MRE11A</i>	miR-520e	693
<i>BBC3</i>	miR-4483	744	<i>HDAC4</i>	miR-302e	2082	<i>NOTCH1</i>	miR-516a-3p	6964
<i>BBC3</i>	miR-4710	796	<i>HDAC4</i>	miR-1205	976	<i>NOTCH1</i>	miR-516b*	6964
<i>BCAS1</i>	miR-4307	871	<i>HDAC4</i>	miR-4472	2159	<i>NOTCH1</i>	miR-4283	1245
<i>BID</i>	miR-596	364	<i>HDAC4</i>	miR-4481	1868	<i>NOTCH1</i>	miR-4455	6381
<i>BIRC7</i>	miR-4456	372	<i>HDAC4</i>	miR-4483	2802	<i>NOTCH1</i>	miR-4455	6997
<i>BRE</i>	miR-3201	878	<i>HDAC4</i>	miR-4746-3p	982	<i>NOTCH1</i>	miR-4472	4308
<i>CCAR1</i>	miR-4463	841	<i>HNF4A</i>	miR-1204	278	<i>NOTCH1</i>	miR-4472	7474
<i>CCAR1</i>	miR-548ak	3272	<i>HNF4A</i>	miR-4456	465	<i>NOTCH1</i>	miR-4736	75
<i>CDH13</i>	miR-4455	2032	<i>HUWE1</i>	miR-320c	3048	<i>PRKG1</i>	miR-599	2933
<i>DCC</i>	miR-1207-3p	3190	<i>HUWE1</i>	miR-320d	3050	<i>PTPRJ</i>	miR-4472	2750
<i>DCC</i>	miR-4318	1684	<i>HUWE1</i>	miR-1279	10486	<i>SLIT3</i>	miR-302e	3310
<i>DCC</i>	miR-4325	2917	<i>HUWE1</i>	miR-4264	6886	<i>SLIT3</i>	miR-302f	3310
<i>DCC</i>	miR-4711-3p	3297	<i>HUWE1</i>	miR-4307	3373	<i>SLIT3</i>	miR-4472	3745
<i>DMD</i>	miR-4282	2958	<i>HUWE1</i>	miR-4443	4959	<i>SLIT3</i>	miR-4481	4872
<i>DMD</i>	miR-4493	5132	<i>HUWE1</i>	miR-4792	10624	<i>SLIT3</i>	miR-4492	1201
<i>DMD</i>	miR-4520a-5p	1878	<i>IGF1R</i>	miR-1268	1535	<i>SLIT3</i>	miR-4508	1201
<i>DMD</i>	miR-4520b-5p	1878	<i>IGF1R</i>	miR-4282	528	<i>SLIT3</i>	miR-4513	499
<i>DMD</i>	miR-4650-5p	5135	<i>IGF1R</i>	miR-4456	462	<i>SPATA13</i>	miR-1261	1854
<i>DNMT3A</i>	miR-302f	3075	<i>LFNG</i>	miR-1274b	175	<i>SPATA13</i>	miR-4266	2070
<i>DNMT3A</i>	miR-665	1570	<i>LFNG</i>	miR-3195	178	<i>SPATA13</i>	miR-4456	2864
<i>DNMT3A</i>	miR-3676	1221	<i>LFNG</i>	miR-4264	1154	<i>TNKS</i>	miR-4455	3891
<i>DNMT3A</i>	miR-4456	2223	<i>LRP1</i>	miR-132	4503	<i>TNKS</i>	miR-4465	1769
<i>EIF4H</i>	miR-645	705	<i>LRP1</i>	miR-1261	7704	<i>TNKS</i>	miR-4531	647
<i>EPHB2</i>	miR-4253	1087	<i>LRP1</i>	miR-4253	10550	-	-	-

**Table 3.** Positions of ig-miRNA binding sites in 3'UTR mRNA.

Target gene	miRNA	Position (nt)	Target gene	miRNA	Position (nt)	Target gene	miRNA	Position (nt)
<i>AATK</i>	miR-4472	4514	<i>EPHB2</i>	miR-4455	4792	<i>IGF1R</i>	miR-4455	8927
<i>AKT2</i>	miR-4316	2472	<i>ERBB4</i>	miR-4279	10500	<i>IGF1R</i>	miR-769-3p	7824
<i>AKT2</i>	miR-4418	3951	<i>ERBB4</i>	miR-568	11012	<i>IGF1R</i>	miR-4455	10709
<i>AKT2</i>	miR-4264	2336	<i>ERBB4</i>	miR-3123	4973	<i>LFNG</i>	miR-466	1269
<i>BBC3</i>	miR-4507	1000	<i>ERBB4</i>	miR-302f	5163	<i>LFNG</i>	miR-4318	1899
<i>BBC3</i>	miR-4505	1000	<i>ERBB4</i>	miR-513a-5p	4123	<i>LRP1</i>	miR-4328	14372
<i>BBC3</i>	miR-4497	965	<i>FBXW7</i>	miR-3674	3468	<i>MAP2K4</i>	miR-1827	3050
<i>BBC3</i>	miR-3676	1616	<i>FOXP1</i>	miR-466	5945	<i>MCM7</i>	miR-4466	2782
<i>BBC3</i>	miR-1587	1000	<i>FOXP1</i>	miR-4266	3217	<i>MRE11A</i>	miR-4456	3832
<i>BBC3</i>	miR-4279	1636	<i>HDAC4</i>	miR-4478	8388	<i>MTUS1</i>	miR-513a-5p	4652
<i>BID</i>	miR-543	2428	<i>HDAC4</i>	miR-4529-5p	6541	<i>MTUS1</i>	miR-4443	6051
<i>BRE</i>	miR-4456	1575	<i>HDAC4</i>	miR-4482	7344	<i>MTUS1</i>	miR-3168	4674
<i>CDH13</i>	miR-297	3603	<i>HDAC4</i>	miR-4710	8162	<i>MTUS1</i>	miR-513b	4652
<i>DCC</i>	miR-302f	6493	<i>HDAC4</i>	miR-4311	7024	<i>NOTCH1</i>	miR-1587	8133
<i>EGFL7</i>	miR-3130-5p	1454	<i>HDAC4</i>	miR-4328	4662	<i>NOTCH1</i>	miR-1275	9070
<i>EIF4H</i>	miR-4309	1364	<i>HNF4A</i>	miR-3934	1350	<i>SPATA13</i>	miR-876-3p	6126
<i>EIF4H</i>	miR-197	1627	<i>IGF1R</i>	miR-4456	7101	-	-	-

had six miRNA binding sites in 3'UTR and three of them were located in same place (miR-4505, miR-4507 and miR-1587). Such part of mRNA is very important for its regulation via several miRNA.

#### Interaction of intronic miRNAs with mRNAs genes coding in-miRNA

Oncogenes (51) are host genes and target genes for in-miRNAs. Majority of these in-miRNAs are encoded in intron. Five of the studied genes (*ATF2*, *BID*, *DMD*, *EVL* and *FOXP1*) encode intronic pre-miRNAs in their 3'UTRs and another five genes (*BBC3*, *EPHB2*, *NR2F2*, *PTPRJ* and *SPATA13*) in their 5'UTRs. Some genes encode one or more in-miRNA. For example, *AATK* gene encodes pre-miR-338, pre-miR-657 and pre-miR-1250; *HDAC4* gene encodes pre-miR-2467, pre-miR-4440 and pre-miR-4441.

Binding sites of 686 in-miRNAs with 51 mRNAs were studied (Table 4). The miRNA binding sites number are significantly different for the studied mRNAs. All parts of the studied mRNAs have similar binding ability to miRNA. In-miRNAs shares were 20.9, 39.5 and 39.5% sites in 5'UTR, CDS, 3'UTR, respectively. The average binding sites densities of 5'UTR, CDS and 3'UTR computed mRNAs were 1.81, 0.61 and 0.73 s/l, respectively. These results indicate that miRNAs can bind to 5'UTR, CDS and 3'UTR. *LRP1* gene has six miRNA binding sites in all parts of its mRNA: 5'UTR (miR-4274), CDS (miR-1273f, miR-4295, miR-4296 and miR-500b) and 3'UTR (miR-4297). *HUWE1* gene has miRNA binding sites (miR-4297, miR-548an and miR-598) only in CDS and *LFNG*

gene had sites (miR-1224-3p, miR-500b) only in 3'UTR. Some mRNAs can be targets to in-miRNAs that encode in different pre-mRNA genes.

The linkages between genes via in-miRNAs are presented in Table 4. Some of the studied mRNAs belong to the host and target genes. For example, *BIRC7* encode in-miR-3196 and is target for in-miR-4292, in-miR-4257 and ig-miR-4456 at the same time. *IGF1R* gene is target for miR-1268B (*CCDC40*), miR-1273F (*SCP2*), miR-3173 (*DICER1*), miR-361 (*CHM*), miR-4292 (*C9orf86*), and miR-4297 (*EBF3*), where gene origin corresponding pre-miRNA is shown in brackets. These data show a linkage between different oncogenes encoded intronic miRNAs, where each mRNA is target for some miRNAs and encodes other miRNAs.

#### Interaction of exonic miRNAs with mRNA genes coding in-miRNA

Binding sites of 49 ex-miRNAs with 51 mRNAs have been studied. The linkages between genes via ex-miRNAs are presented in Table 5. Despite the small number of target genes, these data have proved that ex-miRNA can bind to CDS and 3'UTR, but there is no site in 5'UTR. Only seven out of all ex-miRNAs interact with seven target mRNAs. Shares of binding sites for ex-miRNAs were 75% sites in CDS and 25% sites in 3'UTR of mRNA. *DMD* gene had two miRNA binding sites (miR-4315 and miR-1306). miR-4315 has two target genes (*DMD* and *BIRC6*). *DNMT3A* gene encodes in-miR-1301 and is a target for ex-miR-4775. These data show a linkage between host genes of exonic and intronic miRNA.

**Table 4.** Positions of in-miRNA binding sites in 5'UTR, CDS, 3'UTR mRNA.

<b>Target gene</b>	<b>miRNA</b>	<b>Position (nt)</b>	<b>Host gene</b>
<b>5'UTR</b>			
<i>BIRC7</i>	miR-4292	60	<i>C9orf86</i>
<i>EPCAM</i>	miR-4317	45	<i>L3MBTL4</i>
<i>EPCAM</i>	miR-4753-3p	7	<i>ARID4B</i>
<i>GIPR</i>	miR-26a-1*	25	<i>CTDSPL</i>
<i>HDAC4</i>	miR-1268b	78	<i>CCDC40</i>
<i>HDAC4</i>	miR-1914*	540	<i>UCKL1</i>
<i>HDAC4</i>	miR-4296	53	<i>CTBP2</i>
<i>HDAC4</i>	miR-4296	159	<i>CTBP2</i>
<i>IGF2</i>	miR-1273f	81	<i>SCP2</i>
<i>LRP1</i>	miR-4274	428	<i>SORCS2</i>
<i>PRKG1</i>	miR-1268b	140	<i>CCDC40</i>
<i>PTPRJ</i>	miR-1238	208	<i>ATG4D</i>
<b>CDS</b>			
<i>AATK</i>	miR-4651	4029	<i>POR</i>
<i>ABCA6</i>	miR-3941	3053	<i>PLEKHA1</i>
<i>BBC3</i>	miR-4655-3p	598	<i>MAD1L1</i>
<i>BID</i>	miR-4285	432	<i>SH2B2</i>
<i>BIRC7</i>	miR-4257	745	<i>ADAMTSL4</i>
<i>BRE</i>	miR-4259	315	<i>CCDC19</i>
<i>DMD</i>	miR-4753-3p	11190	<i>ARID4B</i>
<i>DNMT3A</i>	miR-593	674	<i>SND1</i>
<i>ERBB4</i>	miR-3182	3863	<i>CDH13</i>
<i>ERBB4</i>	miR-4797-3p	3376	<i>DLG1</i>
<i>EVL</i>	miR-1322	522	<i>PINX1</i>
<i>EVL</i>	miR-4281	1001	<i>SNCB</i>
<i>GIPR</i>	let-7g	140	<i>WDR82</i>
<i>GIPR</i>	miR-1238	182	<i>ATG4D</i>
<i>LRP1</i>	miR-500b	1824	<i>CLCN5</i>
<i>LRP1</i>	miR-1273f	3301	<i>SCP2</i>
<i>LRP1</i>	miR-4295	6360	<i>VTI1A</i>
<i>NOTCH1</i>	miR-1271	1240	<i>ARL10</i>
<i>NOTCH1</i>	miR-3196	688	<i>BIRC7</i>
<i>PTPRJ</i>	miR-342-5p	459	<i>EVL</i>
<i>SLIT2</i>	miR-4446-3p	4223	<i>SIDT1</i>
<i>SLIT3</i>	miR-500b	426	<i>CLCN5</i>
<i>SPATA13</i>	miR-652	482	<i>TMEM164</i>
<b>3'UTR</b>			
<i>AATK</i>	miR-648	4498	<i>MICAL3</i>
<i>AKT2</i>	miR-3196	1865	<i>BIRC7</i>
<i>AKT2</i>	miR-4281	2711	<i>SNCB</i>
<i>ANTXR1</i>	miR-32*	5217	<i>C9orf5</i>
<i>BBC3</i>	miR-3156-3p	1667	<i>ANKRD30B</i>
<i>CDH13</i>	miR-574-5p	3603	<i>FAM114A1</i>
<i>EBF3</i>	miR-500b	2252	<i>RPS6KA1</i>
<i>EBF3</i>	miR-1976	2260	<i>CLCN5</i>
<i>EGFL7</i>	miR-3130-5p	1454	<i>FASTKD2</i>
<i>EIF4H</i>	miR-4263	1611	<i>BRE</i>
<i>ERBB4</i>	miR-483-3p	10500	<i>IGF2</i>

**Table 4.** Continued.

<i>ERBB4</i>	miR-877*	10504	<i>ABCF1</i>
<i>HDAC4</i>	miR-1289	6515	<i>FSTL4</i>
<i>HDAC4</i>	miR-4326	4606	<i>ARFGAP1</i>
<i>IGF1R</i>	miR-361-3p	7089	<i>CHM</i>
<i>IGF1R</i>	miR-1273f	7624	<i>SCP2</i>
<i>IGF1R</i>	miR-3173-5p	5679	<i>DICER1</i>
<i>IGF1R</i>	miR-4292	6166	<i>C9orf86</i>
<i>IGF2</i>	miR-1273f	1902	<i>SCP2</i>
<i>IGF2</i>	miR-3972	4533	<i>PADI3</i>
<i>IGF2</i>	miR-4263	3055	<i>BRE</i>
<i>IGF2</i>	miR-4296	4307	<i>CTBP2</i>
<i>LFNG</i>	miR-1224-3p	2007	<i>VWA5B2</i>

**Table 5.** Positions of ex-miRNA binding sites in CDS, 3'UTR mRNA.

Target gene	miRNA	Position (nt)	Host gene
<b>CDS</b>			
<i>BIRC6</i>	miR-4315	11064	<i>PLEKHM1</i>
<i>BIRC7</i>	miR-1825	373	<i>POFUT1</i>
<i>DMD</i>	miR-4315	6086	<i>PLEKHM1</i>
<i>DMD</i>	miR-1306	2819	<i>DGCR8</i>
<i>GIPR</i>	miR-671-5p	1236	<i>CHPF2</i>
<i>HUWE1</i>	miR-3652	6967	<i>HSP90B1</i>
<b>3'UTR</b>			
<i>DNMT3A</i>	miR-4775	3420	<i>CCNYL1</i>
<i>MTUS1</i>	miR-1306	5360	<i>DGCR8</i>

### HDAC4 mRNA has three types of miRNA binding sites

As it is known, there exist three types of binding sites: 5'-dominant canonical, 5'-dominant seed only and 3'-compensatory sites (Betel et al., 2010). Canonical site has good (or perfect) complementarity at both the 5'- and 3'-ends of the miRNA with a specific bulge in the middle. Dominant seed site has perfect seed 5'-complementarity to the miRNA but poor 3'-complementarity. Compensatory site has a mismatch (wobble) in the 5'-seed region, but compensate through excellent complementarity at the 3'-end of miRNA.

5'-dominant canonical and 3'-compensatory types of binding sites were found in the obtained data. There is no 5'-dominant seed of binding sites, because such sites have low energy of binding site and are not reliable according to our criteria. In addition, complementary type of miRNA binding sites was found after the analysis of our results. It has perfect complementarity beginning with second nucleotide and completing the last but one nucleotide of miRNA in binding site. There was no bulge in the middle (Table 6). Such binding sites have high energy of binding site and are reliable according to our

criteria.

*HDAC4* mRNA had three types of miRNA binding sites. For example, 5'-dominant canonical sites were in-miR-4296 and ig-miR-3195; 3'-compensatory sites were ig-miR-4311 and in-miR-1914\*; complementary sites were ig-miR-4478 and in-miR-1289 (Table 6). Main contribution to energy can include all parts of miRNA site, but not only 5' seed. *HDAC4* mRNA is a target for several intergenic and intronic miRNAs. In both cases, sites may be found in any region mRNA. The sites found have high hybridization energy due to significant amount of complementary nucleotides.

### DISCUSSION

Expression may be regulated by miRNAs for more than a half of human genes (Friedman et al., 2009). The number of known human miRNAs constantly increases, as well as the number of their potential target genes. The establishment of target genes depends on the efficiency of their prediction by computer methods. Indeed, experimental verification of predicted target genes depends on the accuracy of prediction of miRNA sites

**Table 6.** Schematic representation of types of miRNA bindings sites in mRNA HDAC4.

5'UTR,53 $\Delta G=-33,5$ $\Delta G/\Delta G_m=84$ 5'-d/c	5'UTR,266 $\Delta G=-38,8$ $\Delta G/\Delta G_m=84$ 5'-d/c
mRNA 5' CGAGCCCCGAGCCCCGCGC 3' miR-4296 3' ACUCGGACUCGGGUGUA 5'	MRNA 5' AGCCCCGGCCCGGCGCC 3' miR-3195 3' UUGGGCCCCGGCCGCGC 5'
3'UTR,7024 $\Delta G=-28,8$ $\Delta G/\Delta G_m=80$ 3'-compn.	5'UTR,540 $\Delta G=-46,8$ $\Delta G/\Delta G_m=81$ 3'-compn.
mRNA 5' CACACUCGGCUCUUCUCC 3' miR-4311 3' GUGUGAGUCGAGAGAAAAG 5'	MRNA 5' UCUCCCGGUGCGGGGCCCGCGCC 3' miR-1914* 3' GGAGGGUCACGCCUGGG-GAGG 5'
3'UTR,8388 $\Delta G=-34,6$ $\Delta G/\Delta G_m=87$ compl.	3'UTR,6515 $\Delta G=-36,7$ $\Delta G/\Delta G_m=80$ compl.
mRNA 5' GUUCUAGCUCGGCCUC 3' miR-4478 3' GAGGAGUCGAGUCGGAG 5'	mRNA 5' UGAGUGCAGAUUCUUGGAUUCAC 3' miR-1289 3' UUUUACGUCUAAGGACCUGAGGU 5'

Interaction energy ( $\Delta G$ ) is measured in kcal/mol. The  $\Delta G/\Delta G_m$  value is calculated in percents. Types of binding sites: 5'-d/c – 5'-dominant canonical, 3'-comp. – 3'-compensatory, compl. – complementary site.

and their characteristics considered in corresponding programs. Besides, the essential role of prediction of binding sites and their validation have limitation depending on the quality of prediction (Grimson et al., 2007). Functional regions of mRNAs were shown to be significantly heterogeneous according to the number of binding sites and to the location density of these miRNA sites (Issabekova et al., 2011).

In our work, interaction sites of 1519 miRNAs with 51 mRNA-targets are presented. Majority of these miRNAs were revealed recently (with miRNA index number 1000 and more) and were bad-studied. Total number of miRNA binding sites was found in the studied target genes to be 439. Some miRNAs have several binding sites with the same mRNA. Average number of binding sites was six miRNAs on mRNA. miRNA sites with high  $\Delta G/\Delta G_m$  ratio were selected with  $P < 0.0004$ . In-miRNAs and ig-miRNAs have similar properties. miRNAs with length 22 nt have distinct prevalence concerning others which have bigger or smaller length. A great number of in-miRNAs and ig-miRNAs have a high GC-content (50 to 55%). Most genes under study appear to have binding sites with miRNA. Therefore, it is possible that the expression of a significant part of human genes is under a regulation control by miRNAs. Intergenic miR-4472, miR-4456, miR-4455, miR-302f and miR-3195 had thirteen, nine, seven, six and five target genes accordingly. The expression of such miRNAs can repress translation of some genes participating in cancer development.

The shares of all binding sites (18.4, 58.2 and 23.4%) in 5'UTR, CDS, 3'UTR of the studied mRNA, respectively

were found. Ig-miRNA binding sites were in 3.3 times more than it is to ig-miRNA. Thus, the density of binding sites in 5'UTR was 2.6 times more than it was in CDS and 2.8 times more than it was in 3'UTR. Such data indicate that miRNAs can interact with 5'UTR and CDS, and not only with 3'UTR. Some miRNAs have a high site density in 5'UTR. A significant part of the studied miRNAs interacts with mRNA of only one gene. Effect on such miRNAs would allow selection of modification of associated target genes expression. mRNAs of some genes are targets for ig-miRNAs and in-miRNAs. Majority intronic and exonic miRNAs express together with their host genes. These miRNA provide interaction of 51 host genes of in-miRNA with other host genes via in-miRNAs and ex-miRNAs. Changes in host gene expression lead to changes of intronic and exonic miRNA expression. These processes influence the target genes translation.

## Conclusion

Computational prediction of miRNA binding sites is an important stage in the investigation of biological function miRNA. These data promote understanding the features of gene regulation on post-transcription level via miRNAs. The linkage between different genes encoding in-miRNAs and being targets for in-miRNAs was revealed. These genes participate in different cellular processes and reveal linkages between such genes participating in gastrointestinal cancer.

It was found that the percentage of ig-miRNA, ex-miRNA and in-miRNA sites are approximately identical in 5'UTR,



CDS, and 3'UTR. Approximately 2/3 of these sites bind to 5'UTR or CDS regions. This suggests that sites involved in a translation regulation by miRNAs are located not only in 3'UTR, but in 5'UTR and CDS regions.

According to these data, nearly 45% of miRNAs are intronic and their synthesis directly depends on transcription of corresponding host genes. In-miRNAs had no strong binding to mRNAs of the 51 studied oncogenes. Therefore, in-miRNAs do not inhibit the expression of host genes.

Three types of schemes of interaction between mRNA and miRNA was revealed. There were 5'-dominant canonical sites, 3'-compensatory sites and complementary sites. The primary contribution to energy can include not only 5'seed, but all the parts of miRNA site. Hence, all the parts of miRNA sites can bring contribution to the total energy of binding site ( $\Delta G/\Delta G_m$ ).

High miRNA concentration, that reduce expression of gene-suppressors can be identiec to stimulation of carcinogenesis. The effect of low miRNA concentration on oncogenes can cause the development of cancer. Changes that occur in miRNA concentration can possibly be used as medicines in anti-sense therapy of breast and gastrointestinal tract cancer.

## ACKNOWLEDGEMENTS

This work was supported by a grant from the Ministry of Education and Science, Republic of Kazakhstan. We thank Vladimir Khailenko for creating programs miRNAFinder 2.2 and E-RNAhybrid.

## REFERENCES

- Baek D, Villen J, Shin C, Camargo F, Gygi S, Bartel D (2008). The impact of microRNAs on protein output. *Nature* 455:64-71.
- Betel D, Koppal A, Agius P, Sander C, Bartel CL (2010). Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. *Genome Biol.* pp. 11-R90.
- Cortez MA, Welsh JW, Calin GA (2012). Circulating microRNAs as noninvasive biomarkers in breast cancer. *Cancer Res.* 195:151-161.
- Delay C, Calon F, Matthews P, Hébert S (2011). Alzheimer-specific variants in the 3'UTR of amyloid precursor protein affect microRNA function. *Mol. Neurodegen.* pp. 6-70.
- Duursma A, Kedde M, Schrier M, Sage C, Agami R (2008). miR-148 targets human DNMT3b protein coding region. *RNA* 14:872-877.
- Elcheva I, Goswami F, Noubissi K, Spiegelman V (2009). CRD-BP protects the coding region of  $\beta$ TrCP1 mRNA from miR-183-mediated degradation. *Mol. Cell.* 35:240-246.
- Fang Y, Fang D, Hu J (2012). MicroRNA and its roles in esophageal cancer. *Med. Sci. Monit.* 18:RA22-30.
- Farh KK-H, Grimson A, Jan C, Lewis BP, Johnston WK (2005). The widespread impact of mammalian microRNAs on mRNA repression and evolution. *Sci.* 310:1817-1821.
- Friedman RC, Farh KK, Burge CB, Bartel DP (2009). Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* 19:92-105.
- Garcna D, Baek D, Shin C, Bell G, Grimson A, Bartel D (2011). Weak seed-pairing stability and high target-site abundance decrease the proficiency of Isy-6 and other miRNAs. *Nat. Struct. Mol. Biol.* 18:1139-1146.
- Grimson A, Farh K, Johnston W, Garrett-Engle P, Lim L, Bartel D (2007). MicroRNA targeting specificity in mammals:determinants beyond seed pairing. *Mol. Cell.* 27:91-105.
- Hafez MM, Hassan ZK, Zekri AR, Gaber AA, AL Rejaie SS, Sayed-Ahmed MM (2012). microRNAs and metastasis-related gene expression in Egyptian breast cancer patients. *Asian. Pac. J. Cancer Prev.* 13:591-598.
- Hamano R, Ishii H, Miyata H, Doki Y, Mori M (2011). Role of microRNAs in solid tumors. *J. Nucleic Acids Invest.* pp. 2-e2.
- Hamfjord J, Stan eland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T (2012). Differential expression of miRNAs in colorectal cancer: Comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. *PLoS One.* 7-e34150.
- Hanna JA, Wimberly H, Kumar S, Slack F, Agarwal S, Rimm DL (2012). Quantitative analysis of microRNAs in tissue microarrays by *in situ* hybridization. *Biotechniques* 52:235-245.
- Ibanez-Ventoso C, Vora M, Driscoll M (2008). Sequence relationships among *C. elegans*, *D. melanogaster* and human microRNAs highlight the extensive conservation of microRNAs in biology. *PLoS ONE.* pp. 3-e2818.
- lorio MV, Croce CM (2009). MicroRNAs in cancer:Small molecules with a huge impact. *J. Clin. Oncol.* 27:5848-5856.
- Isik M, Korswagen H, Berezikov E (2010). Expression patterns of intronic microRNAs in *Caenorhabditis elegans*. *Silence* 1:1758-907X.
- Issabekova AS, Berillo OA, Khailenko VA, Atambayeva SA, Regnier M, Ivachshenko AT (2011). Characteristics of intronic and intergenic human miRNAs and features of their interaction with mRNA. *World Acad. Sci. Eng. Technol.* 59:63-66.
- Jiang Q, Hao Y, Wang G, Juan L, Zhang T, Teng M (2010). Prioritization of disease microRNAs through a human phenome-microRNAome network. *BMC Syst. Biol.* pp. 4-S2.
- Kim YK, Kim VN (2007). Processing of intronic microRNAs. *EMBO J.* 26:775-783.
- Kruger J, Rehmsmeier M (2006). RNAhybrid: microRNA target prediction easy, fast and flexible. *Nucleic Acids Res.* 34:W451-454.
- Kulkarni S, Savan R, Qi Y (2011). Differential microRNA regulation of *HLA-C* expression and its association with HIV control. *Nature* 472:495-499.
- Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003). Prediction of mammalian microRNA targets. *Cell* 115:787-798.
- Lu L, Li Y, Li S (2011). Computational identification of potential microRNA network biomarkers for the progression stages of gastric cancer. *Int. J. Data. Min. Bioinform.* 5:519-531.
- Maragkakis M, Vergoulis T, Alexiou P, Reczko M, Plomaritou K, Gousis M (2011). DIANA-microT web server: elucidating microRNA functions through target prediction. *Nucleic. Acids Res.* 37:W27-276.
- Moretti F, Thermann R, Hentze M (2010). Mechanism of translational regulation by miR-2 from sites in the 5' untranslated region or the open reading frame. *RNA* 16:2493-2502.
- Pillai RS, Bhattacharyya ST, Filipowicz W (2007). Repression of protein synthesis by miRNAs: how many mechanisms? *Trends Cell Biol.* 17:118-126.
- Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, Jin Y (2010). miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. *PLoS One.* pp. 5-e9429.
- Rodríguez A, Griffiths-Jones S, Ashurst JL, Bradley A (2004). Identification of mammalian microRNA host genes and transcription units. *Genome Res.* 14:1902-1910.
- Selbach M, Schwanhauser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N (2008). Widespread changes in protein synthesis induced by microRNAs. *Nature* 455:58-63.
- Sethupathy P, Megraw M, Hatzigeorgiou AG (2006). A guide through present computational approaches for the identification of mammalian microRNA targets. *Nat. Methods* 3:881-886.
- Shirdel EA, Xie W, Mak TV, Jurisica I (2011). NAViGaTing the micronome—using multiple microRNA prediction databases to identify signaling pathway-associated microRNAs. *PLoS ONE.* pp. 6-e17429.
- Small EM, Frost RJ, Olson EN (2010). MicroRNAs add a new dimension to cardiovascular disease. *Circulation* 121:1022-1032.
- Tsai NP, Lin YL, Wei LN (2009). MicroRNA mir-346 targets the 5'UTR of *RIP140* mRNA and up-regulates its protein expression. *Biochem. J.* 424:411-418.

## APPENDIX

Supplementary Table 1. Fifty-One (51) Oncogenes coding intronic miRNAs.

Gene	Full name of gene	References
<i>AATK</i>	Apoptosis-associated tyrosine kinase	Lee et al. (2006)
<i>ABCA6</i>	ATP-binding cassette, sub-family A (ABC1), member 6	Hlavata et al. (2012)
<i>ABCF1</i>	ATP-binding cassette, sub-family F (GCN20), member 1	Hlavata et al. (2012)
<i>AKT2</i>	V-akt murine thymoma viral oncogene homolog 2	Li et al. (2011)
<i>ANTXR1</i>	Anthrax toxin receptor 1	Rmali et al. (2004)
<i>ATF2</i>	Activating transcription factor 2	Asting et al. (2011)
<i>BBC3</i>	BCL2 binding component 3	Ray et al. (2011)
<i>BCAS1</i>	Breast carcinoma amplified sequence 1	Correa et al. (2000)
<i>BID</i>	BH3 interacting domain death agonist	Ma et al. (2012)
<i>BIRC6</i>	Baculoviral IAP repeat-containing 6	Van et al. (2011)
<i>BIRC7</i>	Baculoviral IAP repeat containing 7	Oh et al. (2011)
<i>BRE</i>	Brain and reproductive organ-expressed	Yao et al. (2012)
<i>CCAR1</i>	Cell division cycle and apoptosis regulator 1	Ou et al. (2009)
<i>CDH13</i>	Cadherin 13, H-cadherin (heart)	Hibi et al. (2004)
<i>DCC</i>	Deleted in colorectal carcinoma	Derks et al. (2009)
<i>DMD</i>	Dystrophin	Edward et al. (2004)
<i>DNMT3A</i>	DNA (cytosine-5-)-methyltransferase 3 alpha	Schneider-Stock et al. (2005)
<i>DTL</i>	Denticleless homolog (Drosophila)	Baraniskin et al. (2012)
<i>EBF3</i>	Early B-cell factor 3	Kim and Kim (2007)
<i>EGFL7</i>	EGF-like-domain, multiple 7	Díaz et al. (2008)
<i>EIF4H</i>	Eukaryotic translation initiation factor 4H	Wu et al. (2011)
<i>EPCAM</i>	Epithelial cell adhesion molecule	Tao et al. (2012)
<i>EPHB2</i>	EPH receptor B2	Herath et al. (2012)
<i>ERBB4</i>	V-erb-a erythroblastic leukemia viral oncogene homolog 4	Frey et al. (2010)
<i>EVL</i>	Enah/Vasp-like	Yi et al. (2011)
<i>FBXW7</i>	F-box and WD repeat domain containing 7	Milne et al. (2010)
<i>FOXP1</i>	Forkhead box P1	Adams et al. (2009)
<i>GIPR</i>	Gastric inhibitory polypeptide receptor	Prabakaran et al. (2010)
<i>HDAC4</i>	Histone deacetylase 4	Jin et al. (2012)
<i>LFNG</i>	O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase	Reedijk et al. (2008).
<i>HNF4A</i>	Hepatocyte nuclear factor 4, alpha	Weltmeier et al. (2011)
<i>HUWE1</i>	HECT, UBA and WWE domain containing 1	Zhao et al. (2008)
<i>IGF1R</i>	Insulin-like growth factor 1 receptor	Pennarun et al. (2011)
<i>IGF2</i>	Insulin-like growth factor 2 (somatomedin A)	Hoyo et al. (2012)
<i>LRP1</i>	Low density lipoprotein receptor-related protein 1	Toquet et al. (2007)
<i>MAP2K4</i>	Mitogen-activated protein kinase kinase 4	Soh et al. (2001)
<i>MAP7D2</i>	MAP7 domain containing 2	Sjöblom et al. (2006)
<i>MCM7</i>	Minichromosome maintenance complex component 10	Nishihara et al. (2009)
<i>MRE11A</i>	MRE11 meiotic recombination 11 homolog A ( <i>Saccharomyces cerevisiae</i> )	Takemura et al. (2006)
<i>MTUS1</i>	Microtubule associated tumor suppressor 1	Zuern et al. (2010)
<i>NOTCH1</i>	Notch 1p	Zhang et al. (2010)
<i>NR2F2</i>	Nuclear receptor subfamily 2, group F, member 2	Corneza et al. (2008)
<i>PRKG1</i>	Protein kinase, cGMP-dependent, type I	Savas et al. (2010)
<i>PTK2</i>	PTK2 protein tyrosine kinase 2	Leve et al. (2011)
<i>PTPRJ</i>	Protein tyrosine phosphatase, receptor type, J	Jeon et al. (2009)
<i>SDCCAG8</i>	Serologically defined colon cancer antigen 8	Kamio et al. (2010)
<i>SLIT2</i>	Slit homolog 2 (Drosophila)	Li-F et al. (2012)
<i>SLIT3</i>	Slit homolog 3 (Drosophila)	Zhu et al. (2011)
<i>SPATA13</i>	Spermatogenesis associated 13	Kawasaki et al. (2007)
<i>TNFAIP6</i>	Tumor necrosis factor, alpha-induced protein 6	Hamm et al. (2008)
<i>TNKS</i>	TRF1-interacting ankyrin-related ADP-ribose polymerase	Shebzukhov et al. (2008)